No Data
No Data
Guangji Pharmaceutical (000952.SZ) announced first-quarter results with a net loss of 50,5082 million
Guangji Pharmaceutical (000952.SZ) released its report for the first quarter of 2024, achieving an operating income of 1.8 during the reporting period...
Guangji Pharmaceutical (000952.SZ): Appoints Lu Zilong as General Manager
Gelonghui, April 12, 丨 Guangji Pharmaceutical (000952.SZ) announced that the company held the 40th (Provisional) Meeting of the 10th Board of Directors on April 12, 2024 to review and pass the “Proposal on Appointing Mr. Lu Zilong as the Company's General Manager”. Following the qualification review by the nomination committee of the 10th board of directors and the approval of the nominees, the board of directors of the company agreed to appoint Mr. Lu Zilong as the general manager of the company. The term of office will begin on the date of review and approval by the board of directors and end on the date of expiration of the 10th board of directors.
Guangji Pharmaceutical (000952.SZ) appoints Xiong Yi as financial director
Zhitong Finance App News, Guangji Pharmaceutical (000952.SZ) announced that the company's board of directors recently received a written resignation report submitted by the company's director and financial director Hu Mingfeng. Hu Mingfeng applied to resign as the company's financial director due to job changes. After his resignation, Hu Mingfeng continued to serve as the company's director. The company agreed to appoint Xiong Yi as the company's financial director. The term of office will begin on the date of review and approval by the board of directors until the end of the 10th board of directors.
Express News | Guangji Pharmaceutical: Expected net loss of 130 million to 165 million yuan in 2023
Guangji Pharmaceutical (000952.SZ) and related personnel received a warning letter from the Hubei Securities Regulatory Bureau
Guangji Pharmaceutical (000952.SZ) announced that the company recently received from the China Securities Regulatory Commission and the Hubei Regulatory Bureau...
Guangji Pharmaceutical Gets Nod to Produce Entecavir
Hubei Guangji Pharmaceutical (SHE:000952) obtained approval from China's National Medical Products Administration to produce the raw drug material Entecavir. The raw drug ingredient is used to treat a
No Data